Recombinant follitropin alfa and lutropin alfa in fertility treatment

Ahmed Gibreel, Siladitya Bhattacharya

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Recombinant human follicle stimulating hormone (rFSH) and luteinizing hormone (LH), also known as follitropin alpha and lutropin alpha, are manufactured by genetic engineering techniques which ensure high quality and batch to batch consistency. Follitropin alpha can be used for controlled ovarian hyperstimulation in assisted reproduction, ovulation induction for WHO group I and II anovulatory infertility and in men with hypogonadotrophic hypogonadism (HH) or idiopathic oligo-asthenospermia. Current evidence suggests superiority of urinary human menopausal gonadotropin (HMG) over follitropin alpha in controlled ovarian hyperstimulation for IVF in terms of live birth rate per couple. Addition of lutropin to follitropin alpha in an unselected IVF population does not appear to confer any benefit; however, it may have a role in ovulation induction in women with hypothalamic hypogonadism. Urinary HMG preparations (especially currently available highly purified preparations) are more cost effective than rFSH in terms of cost per ongoing pregnancy. However, women using rFSH injection pen devices have higher levels of satisfaction as compared to those using urinary HMG by means of conventional syringes.
Original languageEnglish
Pages (from-to)5-17
Number of pages13
JournalBiologics: Targets & Therapy
Volume4
DOIs
Publication statusPublished - 2010

Keywords

  • infertility
  • follicle stimulating hormone
  • luteinizing hormone
  • follitropin alpha
  • lutropin alpha
  • in-vitro fertilization
  • urinary gonadotrophins

Fingerprint Dive into the research topics of 'Recombinant follitropin alfa and lutropin alfa in fertility treatment'. Together they form a unique fingerprint.

  • Cite this